Non-alcoholic fatty liver disease and its role in the development of cardiovascular diseases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the contribution of non-alcoholic fatty liver disease (NAFLD) to the pathogenesis of cardiovascular complications, as well as to highlight the main approaches to the diagnosis and treatment of NAFLD based on modern literature data.

Key points. NAFLD is the most common chronic liver disease (in developed countries – up to 25–30% of the population). NAFLD is a significant risk factor for insulin resistance (IR), carbohydrate metabolism disorders, dyslipidemia, and adverse cardiovascular outcomes. Treatment of NAFLD includes an impact on the main links of pathogenesis, therefore the main therapeutic strategy is lifestyle changes, weight loss and elimination of IR, the prescription of hepatoprotectors and herbal medicines.

Conclusion. Being a multifactorial disease leading to increased cardiovascular risk, NAFLD should be detected in a timely manner. Treatment of NAFLD can slow the progression of liver disease and reduce the risks of cardiometabolic complications.

Full Text

Restricted Access

About the authors

S. V. Dora

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Heath of Russia

Email: doras2001@mail.ru
ORCID iD: 0000-0002-8249-6075

MD

Russian Federation, Saint Petersburg

G. V. Semikova

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Heath of Russia

Author for correspondence.
Email: doras2001@mail.ru
ORCID iD: 0000-0003-0791-4705

Candidate of Medical Sciences

Russian Federation, Saint Petersburg

Z. V. Shvets

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Heath of Russia

Email: doras2001@mail.ru
ORCID iD: 0009-0007-9218-8133
Russian Federation, Saint Petersburg

I. V. Cherebillo

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Heath of Russia

Email: doras2001@mail.ru
Russian Federation, Saint Petersburg

N. M. Khoshafyan

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Heath of Russia

Email: doras2001@mail.ru
Russian Federation, Saint Petersburg

References

  1. Ивашкин В.Т., Маевская М.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022; 32 (4): 104–40 [Ivashkin V.T., Maevskaya M.V., Zharkova M.S. et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022; 32 (4): 104–40 (in Russ.)]. doi: 10.22416/1382-4376-2022-32-4-104-140
  2. Luo J., Xu L., Li J. et al. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol. 2015; 27 (3): 193–9. doi: 10.1097/MEG.0000000000000254
  3. Targher G., Byrne C.D., Lonardo A. et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65 (3): 589–600. doi: 10.1016/j.jhep.2016.05.013
  4. Povsic M., Wong O.Y., Perry R. et al. Structured Literature Review of the Epidemiology and Disease Burden of NonAlcoholic Steatohepatitis (NASH). Adv Ther. 2019; 36 (7): 1574–94. doi: 10.1007/s12325-019-00960-3
  5. Hamaguchi M., Kojima T., Takeda N. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13 (10): 1579–84. doi: 10.3748/wjg.v13.i10.1579
  6. Eslam M., Sanyal A.J., George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020; 158 (7): 1999–2014.e1. doi: 10.1053/j.gastro.2019.11.312
  7. Киселева Е.В., Демидова Т.Ю. Неалкогольная жировая болезнь печени и сахарный диабет 2 типа: проблема сопряженности и этапности развития. Ожирение и метаболизм. 2021; 18 (3): 313–9 [Kiseleva E.V., Demidova T.Y. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the problem of conjunction and phasing. Obesity and metabolism. 2021; 18 (3): 313–9 (in Russ.)]. doi: 10.14341/omet12758
  8. Bril F., Ortiz-Lopez C., Lomonaco R. et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015; 35 (9): 2139–46. doi: 10.1111/liv.12840
  9. Kenneally S., Sier J.H., Moore J.B. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. BMJ Open Gastroenterol. 2017; 4 (1): e000139. doi: 10.1136/bmjgast-2017-000139
  10. Ryan M.C., Itsiopoulos C., Thodis T. et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013; 59 (1): 138–43. doi: 10.1016/j.jhep.2013.02.012
  11. Smart N.A., King N., McFarlane J.R. et al. Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: a systematic review and meta-analysis. Br J Sports Med. 2018; 52 (13): 834–43. doi: 10.1136/bjsports-2016-096197
  12. Polyzos S.A., Kang E.S., Boutari C. et al. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism. 2020; 111S: 154203. doi: 10.1016/j.metabol.2020.154203
  13. Armstrong M.J., Gaunt P., Aithal G.P. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebocontrolled phase 2 study. Lancet. 2016; 387 (10019): 679–90. doi: 10.1016/S0140-6736(15)00803-X
  14. Newsome P.N., Buchholtz K., Cusi K. et al. NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021; 384 (12): 1113–24. doi: 10.1056/NEJMoa2028395
  15. Musso G., Cassader M., Paschetta E. et al. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017; 177 (5): 633–40. doi: 10.1001/jamainternmed.2016.9607
  16. Sanyal A.J., Chalasani N., Kowdley K.V. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362 (18): 1675–85. doi: 10.1056/NEJMoa0907929
  17. Rockey D.C. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol. 2005; 3 (2): 95–107. doi: 10.1016/s1542-3565(04)00445-8
  18. Zois C., Baltayiannis G., Karayiannis P. et al. Systematic review: hepatic fibrosis – regression with therapy. Aliment Pharmacol Ther. 2008; 28 (10): 1175–87. doi: 10.1111/j.1365-2036.2008.03840.x
  19. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020; 1 (38): 7–42 [Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. The Journal of Atherosclerosis and Dyslipidemias. 2020; 1 (38): 7–42 (in Russ.)] doi: 10.34687/2219-8202.JAD.2020.01.0002
  20. Барановский А.Ю., Райхельсон К.Л., Марченко Н.В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии. 2010; 9 (1): 3–10 [Baranovsky A.Yu., Raykhelson K.L., Marchenko N.V. Application of S-adenosylmethionine (Heptral®) in treatment of patients with non-alcoholic steatohepatitis. Klinicheskie perspektivy gastroenterologii, gepatologii. 2010; 9 (1): 3–10 (in Russ.)]
  21. Полубояринов П.А., Моисеева И.Я., Федоров А.В. и др. Астрагал шерстистоцветковый (Astragalus dasyanthus Pell.) – наиболее перспективный источник нетоксичного органического селена. Медицинская сестра. 2023; 25 (6): 46–51 [Poluboyarinov P.A., Moiseeva I.Ya., Fedorov A.V. et al. Woolly-flowered astragalus (Astragalus dasyanthus Pell.) is the most promising source of non-toxic organic selenium. Meditsinskaya sestra. 2023; 25 (6): 46–51 (in Russ.)]. doi: 10.29296/25879979-2023-06-09
  22. Полубояринов П.А., Елистратов Д.Г. Исследование биофортификации растений астрагала шерстистоцветкового (Astragalus dasyanthus Pall.) аминокислотой L-селеноцистином. Вопросы биологической, медицинской и фармацевтической химии. 2019; 22 (12): 64 [Poluboyarinov P.A., Elistratov D.G. Study of biofortification of Astragalus dasyanthus Pall. plants with the amino acid L-selenocystin. Problems of Biological Medical and Pharmaceutical Chemistry. 2019; 22 (12): 64 (in Russ.)].
  23. Song Q.H., Kobayashi T., Iijima K. et al. Hepatoprotective effects of Inula britannica on hepatic injury in mice. Phytother Res. 2000; 14 (3): 180–6. doi: 10.1002/(sici)1099-1573(200005)14:3<180::aid-ptr589>3.0.co;2-h
  24. Соколов С.Я., Замотаев И.П. Справочник по лекарственным растениям (Фитотерапия). 2-е изд., стереотипн. М.: Медицина, 1988; 464 с. [Sokolov S.Ya., Zamotaev I.P. Handbook of medicinal plants (Phytotherapy). 2nd ed., stereotypical. M.: Meditsina, 1988; 464 p. (in Russ.)].
  25. Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125 (6): 1401–12. doi: 10.1093/jn/125.6.1401
  26. Mitsuoka T., Hidaka H., Eida T. Effect of fructo-oligosaccharides on intestinal microflora. Nahrung. 1987; 31 (5–6): 427–36. doi: 10.1002/food.19870310528
  27. Marteau P., Jacobs H., Cazaubiel M. et al. Effects of chicory inulin in constipated elderly people: a double-blind controlled trial. Int J Food Sci Nutr. 2011; 62 (2): 164–70. doi: 10.3109/09637486.2010.527323
  28. Butzner J.D., Parmar R., Bell C.J. et al. Butyrate enema therapy stimulates mucosal repair in experimental colitis in rat. Gut. 1996; 38 (4): 568–73. doi: 10.1136/gut.38.4.568
  29. Kobayashi H., Tan E.M., Fleming S.E. Sodium butyrate inhibits cell growth and stimulates p21WAF1/CIP1 protein in human colonic adenocarcinoma cells indipendently of p53 status. Nutr Cancer. 2003; 46 (2): 202–11. doi: 10.1207/S15327914NC4602_14
  30. Flamm G., Glinsmann W., Kritchevsky D., et al. Inulin and oligofructose as dietary fibre: a review of the evidence. Crit Rev Food Sci Nutr. 2001; 41 (5): 353–62. doi: 10.1080/20014091091841
  31. Касьянов Г.И., Сязин И.Е., Лугинин М.И. и др. Технология криообработки и криопереработки растительного сырья. Современные научные исследования и инновации. 2012; 3 [Электронный ресурс] [Kasyanov G.I., Syazin I.E., Luginin M.I. et al. Technology of cryoprocessing and cryoprocessing of plant raw materials. Modern scientific researches and innovations. 2012; 3 [Electronic resource] (in Russ.)]. URL: http://web.snauka.ru/issues/2012/03/10751 (Access date: 26.10.2023)
  32. Осецкий А.И., Грищенко В.И., Гольцев А.Н. и др. Криогенные технологии в производстве фармацевтических, косметических, агротехнических препаратов и биологически активных пищевых добавок. Проблемы криобиологии. 2009; 19 (4): 488–99 [Osetsky A.I., Grishchenko V.I., Goltsev A.N. et al. Cryogenic technologies in production of pharmaceutical, cosmetic, agrotechnical formulations and biologically active food additives. Problems of Cryobiology. 2009; 19 (4): 488–99 (in Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Pathogenetic mechanisms of the formation of NAFLD (adapted from [6])

Download (20KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies